Platelet-Mediated Modulation of Fibrinolysis

Abstract

Platelets are crucial to the hemostatic response. Their role in coagulation is well documented and they have been considered for some time to promote resistance of thrombi to fibrinolysis. Platelets confer resistance to lysis by promoting clot retraction of the immediate fibrin network and through release of plasminogen activator inhibitor-1 from their α-granules. However, recent developments in the field indicate that the role of platelets in fibrinolysis is much more diverse. Indeed, novel studies suggest that platelets form different subpopulations upon activation that play varied roles in regulating hemostasis. Likewise the developments in our understanding of thrombus formation, architecture, and changes in fibrin deposition and composition suggest that these different subpopulations of platelets may populate distinct areas within thrombi and potentially dictate the local hemostatic balance in these areas. This review will discuss the diverse roles of platelets in fibrinolysis and highlight the recent developments in the field and the contribution of both the intracellular pool of modulators as well as the membrane surface in regulating these processes.

Keywords

platelets - fibrinolysis - factor XIII - plasminogen - fibrinogen

• References

• 1 Capodanno D, Ferreiro JL, Angiolillo DJ. Antiplatelet therapy: new pharmacological agents and changing paradigms. J Thromb Haemost 2013; 11 (Suppl. 01) 316-329
• 2 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70 (3) 327-333
• 3 Schmaier AH, Amenta S, Xiong T, Heda GD, Gewirtz AM. Expression of platelet C1 inhibitor. Blood 1993; 82 (2) 465-474
• 4 Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101 (12) 4844-4846
• 5 Baeten KM, Richard MC, Kanse SM, Mutch NJ, Degen JL, Booth NA. Activation of single-chain urokinase-type plasminogen activator by platelet-associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets. J Thromb Haemost 2010; 8 (6) 1313-1322
• 6 Whyte CS, Swieringa F, Mastenbroek TG , et al. Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow. Blood 2015; 125 (16) 2568-2578
• 7 Collet JP, Park D, Lesty C , et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20 (5) 1354-1361
• 8 Ono A, Westein E, Hsiao S , et al. Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. Blood 2008; 112 (1) 90-99
• 9 Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Curr Opin Cell Biol 1992; 4 (5) 766-771
• 10 Shattil SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost 1999; 82 (2) 318-325
• 11 Knezevic I, Leisner TM, Lam SC. Direct binding of the platelet integrin alphaIIbbeta3 (GPIIb-IIIa) to talin. Evidence that interaction is mediated through the cytoplasmic domains of both alphaIIb and beta3. J Biol Chem 1996; 271 (27) 16416-16421
• 12 Kasahara K, Kaneda M, Miki T , et al. Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood 2013; 122 (19) 3340-3348
• 13 Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989; 62 (4) 1083-1087
• 14 Blinc A, Keber D, Lahajnar G, Zupancic I, Zorec-Karlovsek M, Demsar F. Magnetic resonance imaging of retracted and nonretracted blood clots during fibrinolysis in vitro. Haemostasis 1992; 22 (4) 195-201
• 15 Aoki N. Clot retraction increases clot resistance to fibrinolysis by condensing alpha 2-plasmin inhibitor crosslinked to fibrin. Thromb Haemost 1993; 70 (2) 376
• 16 Kunitada S, FitzGerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992; 79 (6) 1420-1427
• 17 Frojmovic MM, Milton JG. Human platelet size, shape, and related functions in health and disease. Physiol Rev 1982; 62 (1) 185-261
• 18 Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 1987; 164 (1) 189-195
• 19 Leven RM, Schick PK, Budzynski AZ. Fibrinogen biosynthesis in isolated guinea pig megakaryocytes. Blood 1985; 65 (2) 501-504
• 20 Chiu HC, Schick PK, Colman RW. Biosynthesis of factor V in isolated guinea pig megakaryocytes. J Clin Invest 1985; 75 (2) 339-346
• 21 Handagama PJ, George JN, Shuman MA, McEver RP, Bainton DF. Incorporation of a circulating protein into megakaryocyte and platelet granules. Proc Natl Acad Sci U S A 1987; 84 (3) 861-865
• 22 Handagama PJ, Shuman MA, Bainton DF. Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules. J Clin Invest 1989; 84 (1) 73-82
• 23 George JN, Saucerman S. Platelet IgG, IgA, IgM, and albumin: correlation of platelet and plasma concentrations in normal subjects and in patients with ITP or dysproteinemia. Blood 1988; 72 (1) 362-365
• 24 Sehgal S, Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost 2007; 5 (10) 2009-2016
• 25 Italiano Jr JE, Richardson JL, Patel-Hett S , et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111 (3) 1227-1233
• 26 Harrison P, Wilbourn B, Debili N , et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 1989; 84 (4) 1320-1324
• 27 Nachman RL, Marcus AJ, Zucker-Franklin D. Immunologic studies of proteins associated with subcellular fractions of normal human platelets. J Lab Clin Med 1967; 69 (4) 651-658
• 28 James HL, Ganguly P, Jackson CW. Characterization and origin of fibrinogen in blood platelets. A review with recent data. Thromb Haemost 1977; 38 (4) 939-954
• 29 Lopaciuk S, Lovette KM, McDonagh J, Chuang HY McDonagh. Subcellular distribution of fibrinogen and factor XIII in human blood platelets. Thromb Res 1976; 8 (4) 453-465
• 30 Kaplan KL, Broekman MJ, Chernoff A, Lesznik GR, Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood 1979; 53 (4) 604-618
• 31 Karpatkin M, Howard L, Karpatkin S. Studies of the origin of platelet-associated fibrinogen. J Lab Clin Med 1984; 104 (2) 223-237
• 32 Disdier M, Legrand C, Bouillot C, Dubernard V, Pidard D, Nurden AT. Quantitation of platelet fibrinogen and thrombospondin in Glanzmann's thrombasthenia by electroimmunoassay. Thromb Res 1989; 53 (6) 521-533
• 33 George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75 (7) 1383-1395
• 34 Cramer EM, Debili N, Martin JF , et al. Uncoordinated expression of fibrinogen compared with thrombospondin and von Willebrand factor in maturing human megakaryocytes. Blood 1989; 73 (5) 1123-1129
• 35 Handagama P, Scarborough RM, Shuman MA, Bainton DF. Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa). Blood 1993; 82 (1) 135-138
• 36 Coller BS, Seligsohn U, West SM, Scudder LE, Norton KJ. Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia: evidence consistent with specific roles for glycoprotein IIb/IIIA and alpha v beta 3 integrins in platelet protein trafficking. Blood 1991; 78 (10) 2603-2610
• 37 Maynard DM, Heijnen HF, Horne MK, White JG, Gahl WA. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost 2007; 5 (9) 1945-1955
• 38 Veljkovic DK, Rivard GE, Diamandis M, Blavignac J, Cramer-Bordé EM, Hayward CP. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood 2009; 113 (7) 1535-1542
• 39 Coppinger JA, Cagney G, Toomey S , et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103 (6) 2096-2104
• 40 Robbins KC, Bernabe P, Arzadon L, Summaria L. NH2-terminal sequences of mammalian plasminogens and plasmin S-carboxymethyl heavy (A) and light (B) chain derivatives. A re-evaluation of the mechanism of activation of plasminogen. J Biol Chem 1973; 248 (20) 7242-7246
• 41 Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242 (10) 2333-2342
• 42 Jang IK, Gold HK, Ziskind AA , et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79 (4) 920-928
• 43 Tomkins AJ, Schleicher N, Murtha L , et al. Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke. Exp Transl Stroke Med 2015; 7: 2
• 44 Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104 (13) 3943-3948
• 45 Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S. Platelets retain high levels of active plasminogen activator inhibitor 1. PLoS One 2011; 6 (11) e26762
• 46 Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71 (1) 220-225
• 47 Robbie LA, Young SP, Bennett B, Booth NA. Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and RAI-1 content and distribution. Thromb Haemost 1997; 77 (3) 510-515
• 48 Booth NA, Robbie LA, Croll AM, Bennett B. Lysis of platelet-rich thrombi: the role of PAI-1. Ann N Y Acad Sci 1992; 667: 70-80
• 49 Robbie LA, Bennett B, Croll AM, Brown PA, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 75 (1) 127-133
• 50 Plow EF, Collen D. The presence and release of alpha 2-antiplasmin from human platelets. Blood 1981; 58 (6) 1069-1074
• 51 Gogstad GO, Stormorken H, Solum NO. Platelet alpha 2-antiplasmin is located in the platelet alpha-granules. Thromb Res 1983; 31 (2) 387-390
• 52 Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin. Thromb Haemost 1992; 68 (3) 315-320
• 53 Reed GL, Matsueda GR, Haber E. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis. Trans Assoc Am Physicians 1991; 104: 21-28
• 54 Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mutch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood 2014; 124 (26) 3982-3990
• 55 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271 (28) 16603-16608
• 56 Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274 (49) 35046-35052
• 57 Nesheim M. Fibrinolysis and the plasma carboxypeptidase. Curr Opin Hematol 1998; 5 (5) 309-313
• 58 Schadinger SL, Lin JH, Garand M, Boffa MB. Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. J Thromb Haemost 2010; 8 (11) 2523-2529
• 59 Leung LL, Harpel PC, Nachman RL. Platelet histidine-rich glycoprotein. Methods Enzymol 1989; 169: 268-276
• 60 Leung LL, Harpel PC, Nachman RL, Rabellino EM. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62 (5) 1016-1021
• 61 Lerch PG, Nydegger UE, Kuyas C, Haeberli A. Histidine-rich glycoprotein binding to activated human platelets. Br J Haematol 1988; 70 (2) 219-224
• 62 Tsuchida-Straeten N, Ensslen S, Schäfer C , et al. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 2005; 3 (5) 865-872
• 63 Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986; 77 (4) 1305-1311
• 64 Vu TT, Stafford AR, Leslie BA, Kim PY, Fredenburgh JC, Weitz JI. Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain. J Biol Chem 2011; 286 (35) 30314-30323
• 65 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980; 255 (21) 10214-10222
• 66 Jones AL, Hulett MD, Altin JG, Hogg P, Parish CR. Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein. J Biol Chem 2004; 279 (37) 38267-38276
• 67 Schmaier AH, Smith PM, Colman RW. Platelet C1- inhibitor. A secreted alpha-granule protein. J Clin Invest 1985; 75 (1) 242-250
• 68 Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984; 37 (7) 772-777
• 69 Booth NA, Walker E, Maughan R, Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood 1987; 69 (6) 1600-1604
• 70 Huisman LG, van Griensven JM, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995; 73 (3) 466-471
• 71 Gurewich V, Pannell R, Simmons-Byrd A, Sarmientos P, Liu JN, Badylak SF. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator. J Thromb Haemost 2006; 4 (7) 1559-1565
• 72 Gurewich V. Fibrinolytic mechanisms of tPA, prouPA, mutant prouPA and their implications for therapeutic thrombolysis. Cardiovasc Eng Technol 2013; 4 (4) 328-338
• 73 Bouton MC, Boulaftali Y, Richard B, Arocas V, Michel JB, Jandrot-Perrus M. Emerging role of serpinE2/protease nexin-1 in hemostasis and vascular biology. Blood 2012; 119 (11) 2452-2457
• 74 Gronke RS, Knauer DJ, Veeraraghavan S, Baker JB. A form of protease nexin I is expressed on the platelet surface during platelet activation. Blood 1989; 73 (2) 472-478
• 75 Mansilla S, Boulaftali Y, Venisse L , et al. Macrophages and platelets are the major source of protease nexin-1 in human atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2008; 28 (10) 1844-1850
• 76 Boulaftali Y, Adam F, Venisse L , et al. Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood 2010; 115 (1) 97-106
• 77 Boulaftali Y, Ho-Tin-Noe B, Pena A , et al. Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis. Circulation 2011; 123 (12) 1326-1334
• 78 Kornberg A, Rao NN, Ault-Riché D. Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem 1999; 68: 89-125
• 79 Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279 (43) 44250-44257
• 80 Müller F, Mutch NJ, Schenk WA , et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139 (6) 1143-1156
• 81 Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 2006; 103 (4) 903-908
• 82 Smith SA, Choi SH, Davis-Harrison R , et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116 (20) 4353-4359
• 83 Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariëns RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115 (19) 3980-3988
• 84 Engel R, Brain CM, Paget J, Lionikiene AS, Mutch NJ. Single-chain factor XII exhibits activity when complexed to polyphosphate. J Thromb Haemost 2014; 12 (9) 1513-1522
• 85 Nickel KF, Spronk HM, Mutch NJ, Renné T. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122 (23) 3847-3849
• 86 Tans G, Rosing J. Structural and functional characterization of factor XII. Semin Thromb Hemost 1987; 13 (1) 1-14
• 87 Goldsmith Jr GH, Saito H, Ratnoff OS. The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments. J Clin Invest 1978; 62 (1) 54-60
• 88 Konings J, Hoving LR, Ariëns RS , et al. The role of activated coagulation factor XII in overall clot stability and fibrinolysis. Thromb Res 2015; 136 (2) 474-480
• 89 Mitchell JL, Lionikiene AS, Georgiev G, Klemmer A, Brain C, Kim PY, Mutch NJ. Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity. Blood 2016; 128 (24) 2834-2845
• 90 Pisano JJ, Finlayson JS, Peyton MP. [Cross-link in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine]. Science 1968; 160 (3830): 892-893
• 91 Pisano JJ, Finlayson JS, Peyton MP. Chemical and enzymic detection of protein cross-links. Measurement of epsilon-(gamma-glutamyl)lysine in fibrin polymerized by factor XIII. Biochemistry 1969; 8 (3) 871-876
• 92 Buluk K. [An unknown action of blood platelets; preliminary communication]. Pol Tyg Lek (Wars) 1955; 10 (6) 191
• 93 Luscher EF. [Fibrin-stabilizing factor from thrombocytes]. Schweiz Med Wochenschr 1957; 87 (39–40): 1220-1221
• 94 Kiesselbach TH, Wagner RH. Fibrin-stabilizing factor: a thrombin-labile platelet protein. Am J Physiol 1966; 211 (6) 1472-1476
• 95 Katona E E, Ajzner E, Tóth K, Kárpáti L, Muszbek L. Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. J Immunol Methods 2001; 258 (1–2): 127-135
• 96 Sixma JJ, van den Berg A, Schiphorst M, Geuze HJ, McDonagh J. Immunocytochemical localization of albumin and factor XIII in thin cryo sections of human blood platelets. Thromb Haemost 1984; 51 (3) 388-391
• 97 Marx G, Korner G, Mou X, Gorodetsky R. Packaging zinc, fibrinogen, and factor XIII in platelet alpha-granules. J Cell Physiol 1993; 156 (3) 437-442
• 98 Joist JH, Niewiarowski S. Retention of platelet fibrin stabilizing factor during the platelet release reaction and clot retraction. Thromb Diath Haemorrh 1973; 29 (3) 679-683
• 99 Kaetsu H, Hashiguchi T, Foster D, Ichinose A. Expression and release of the a and b subunits for human coagulation factor XIII in baby hamster kidney (BHK) cells. J Biochem 1996; 119 (5) 961-969
• 100 Cordell PA, Kile BT, Standeven KF, Josefsson EC, Pease RJ, Grant PJ. Association of coagulation factor XIII-A with Golgi proteins within monocyte-macrophages: implications for subcellular trafficking and secretion. Blood 2010; 115 (13) 2674-2681
• 101 Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65 (2) 290-297
• 102 Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 1998; 273 (42) 27220-27224
• 103 Ritchie H, Robbie LA, Kinghorn S, Exley R, Booth NA. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin. Thromb Haemost 1999; 81 (1) 96-103
• 104 Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking. Blood 2011; 117 (23) 6371-6374
• 105 Mutch NJ, Koikkalainen JS, Fraser SR , et al. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost 2010; 8 (9) 2017-2024
• 106 Hevessy Z, Haramura G, Boda Z, Udvardy M, Muszbek L. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. Thromb Haemost 1996; 75 (1) 161-167
• 107 Francis CW, Marder VJ. Rapid formation of large molecular weight alpha-polymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII. J Clin Invest 1987; 80 (5) 1459-1465
• 108 Rubens FD, Perry DW, Hatton MW, Bishop PD, Packham MA, Kinlough-Rathbone RL. Platelet accumulation on fibrin-coated polyethylene: role of platelet activation and factor XIII. Thromb Haemost 1995; 73 (5) 850-856
• 109 Chang JY, Monroe DM, Oliver JA, Roberts HR. TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost 1999; 81 (1) 45-49
• 110 Maroney SA, Ferrel JP, Collins ML, Mast AE. Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans. J Thromb Haemost 2008; 6 (8) 1344-1351
• 111 Maroney SA, Haberichter SL, Friese P , et al. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 2007; 109 (5) 1931-1937
• 112 Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Mast AE. Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth. Arterioscler Thromb Vasc Biol 2011; 31 (4) 821-826
• 113 Vadivel K, Ponnuraj SM, Kumar Y , et al. Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis. J Biol Chem 2014; 289 (45) 31647-31661
• 114 Grau E, Moroz LA. Fibrinolytic activity of normal human blood monocytes. Thromb Res 1989; 53 (2) 145-162
• 115 Manchanda N, Schwartz BS. Lipopolysaccharide-induced modulation of human monocyte urokinase production and activity. J Immunol 1990; 145 (12) 4174-4180
• 116 Larsson LI, Skriver L, Nielsen LS, Grøndahl-Hansen J, Kristensen P, Danø K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 1984; 98 (3) 894-903
• 117 Lijnen HR, Van Hoef B, Collen D. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin. Eur J Biochem 1987; 169 (2) 359-364
• 118 Diamandis M, Veljkovic DK, Maurer-Spurej E, Rivard GE, Hayward CP. Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagul Fibrinolysis 2008; 19 (2) 109-119
• 119 Hayward CP, Cramer EM, Kane WH , et al. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood 1997; 89 (4) 1243-1253
• 120 Gurewich V, Emmons F, Pannell R. Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: Demonstration of a promoting effect by t-PA and by platelets on urokinase. Fibrinolysis 1988; 2 (3) 143-149
• 121 Park S, Harker LA, Marzec UM, Levin EG. Demonstration of single chain urokinase-type plasminogen activator on human platelet membrane. Blood 1989; 73 (6) 1421-1425
• 122 Jiang Y, Pannell R, Liu JN, Gurewich V. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. Blood 1996; 87 (7) 2775-2781
• 123 Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett 1993; 318 (3) 317-321
• 124 Lenich C, Liu JN, Gurewich V. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Blood 1997; 90 (9) 3579-3586
• 125 Levin EG, Loskutoff DJ. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982; 94 (3) 631-636
• 126 Jeanneau C, Sultan Y. Tissue plasminogen activator in human megakaryocytes and platelets: immunocytochemical localization, immunoblotting and zymographic analysis. Thromb Haemost 1988; 59 (3) 529-534
• 127 Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257 (6) 2920-2925
• 128 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257 (6) 2912-2919
• 129 Gao SW, Morser J, McLean K, Shuman MA. Differential effect of platelets on plasminogen activation by tissue plasminogen activator, urokinase, and streptokinase. Thromb Res 1990; 58 (4) 421-433
• 130 Vaughan DE, Mendelsohn ME, Declerck PJ, Van Houtte E, Collen D, Loscalzo J. Characterization of the binding of human tissue-type plasminogen activator to platelets. J Biol Chem 1989; 264 (27) 15869-15874
• 131 Deguchi K, Shirakawa S. Plasminogen activation by tissue plasminogen activator in the presence of platelets. Thromb Res 1988; 8: 65-72
• 132 Hajjar KA, Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med 1999; 9 (5) 128-138
• 133 Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 2002; 90 (4) 428-434
• 134 Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000; 95 (5) 1694-1702
• 135 Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. J Biol Chem 2004; 279 (29) 30697-30706
• 136 Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol 2005; 25 (4) 861-866
• 137 Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood 1997; 90 (7) 2615-2625
• 138 Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122 (2) 429-436
• 139 Munnix IC, Kuijpers MJ, Auger J , et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol 2007; 27 (11) 2484-2490
• 140 Collet JP, Montalescot G, Lesty C , et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 2001; 21 (1) 142-148
• 141 Siljander P, Farndale RW, Feijge MA , et al. Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol 2001; 21 (4) 618-627
• 142 Berny MA, Munnix IC, Auger JM , et al. Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One 2010; 5 (4) e10415
• 143 Cosemans JM, Schols SE, Stefanini L , et al. Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood 2011; 117 (2) 651-660
• 144 Mattheij NJ, Swieringa F, Mastenbroek TG , et al. Coated platelets function in platelet-dependent fibrin formation via integrin αIIbβ3 and transglutaminase factor XIII. Haematologica 2016; 101 (4) 427-436
• 145 Shi J, Pipe SW, Rasmussen JT, Heegaard CW, Gilbert GE. Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure. J Thromb Haemost 2008; 6 (7) 1167-1174
• 146 Kuijpers MJ, Munnix IC, Cosemans JM , et al. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. Microcirculation 2008; 15 (4) 269-282
• 147 Dale GL, Friese P, Batar P , et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415 (6868): 175-179
• 148 Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005; 3 (10) 2185-2192
• 149 Szasz R, Dale GL. Thrombospondin and fibrinogen bind serotonin-derivatized proteins on COAT-platelets. Blood 2002; 100 (8) 2827-2831
• 150 Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11 (1) 2-16
• 151 Prodan CI, Dale GL. Coated-platelets in ischemic stroke - potential insight into the etiology of stroke subtypes. Int J Stroke 2008; 3 (4) 249-250
• 152 Brooks MB, Catalfamo JL, Friese P, Dale GL. Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mitochondrial depolarization. J Thromb Haemost 2007; 5 (9) 1972-1974
• 153 Abaeva AA, Canault M, Kotova YN , et al. Procoagulant platelets form an α-granule protein-covered “cap” on their surface that promotes their attachment to aggregates. J Biol Chem 2013; 288 (41) 29621-29632
• 154 Podoplelova NA, Sveshnikova AN, Kotova YN , et al. Coagulation factors bound to procoagulant platelets are concentrated in their cap structures to promote clotting. Blood 2013; 128 (13) 1745-1755
• 155 Mattheij NJ, Gilio K, van Kruchten R , et al. Dual mechanism of integrin αIIbβ3 closure in procoagulant platelets. J Biol Chem 2013; 288 (19) 13325-13336
• 156 Miles LA, Ginsberg MH, White JG, Plow EF. Plasminogen interacts with human platelets through two distinct mechanisms. J Clin Invest 1986; 77 (6) 2001-2009
• 157 Stalker TJ, Traxler EA, Wu J , et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood 2013; 121 (10) 1875-1885
• 158 Stalker TJ, Welsh JD, Tomaiuolo M , et al. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. Blood 2014; 124 (11) 1824-1831
• 159 van Gestel MA, Heemskerk JW, Slaaf DW , et al. Real-time detection of activation patterns in individual platelets during thromboembolism in vivo: differences between thrombus growth and embolus formation. J Vasc Res 2002; 39 (6) 534-543
• 160 Niiya K, Hodson E, Bader R , et al. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 1987; 70 (2) 475-483
• 161 Mazzucato M, Pradella P, Cozzi MR, De Marco L, Ruggeri ZM. Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor. Blood 2002; 100 (8) 2793-2800
• 162 Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260 (7) 4303-4311
• 163 Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985; 65 (1) 32-40
• 164 Plow EF, Doeuvre L, Das R. So many plasminogen receptors: why?. J Biomed Biotechnol 2012; 2012: 141806
• 165 Potter van Loon BJ, Rijken DC, Brommer EJ, van der Maas AP. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 1992; 67 (1) 101-105
• 166 Dejouvencel T, Doeuvre L, Lacroix R , et al. Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood 2010; 115 (10) 2048-2056
• 167 Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood 1986; 68 (1) 275-280
• 168 Ouimet H, Freedman JE, Loscalzo J. Kinetics and mechanism of platelet-surface plasminogen activation by tissue-type plasminogen activator. Biochemistry 1994; 33 (10) 2970-2976
• 169 Loscalzo J, Pasche B, Ouimet H, Freedman JE. Platelets and plasminogen activation. Thromb Haemost 1995; 74 (1) 291-293
• 170 Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103 (6, Pt 1): 2411-2420
• 171 Hall SW, Humphries JE, Gonias SL. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J Biol Chem 1991; 266 (19) 12329-12336
• 172 Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99 (23) 3050-3055
• 173 Podor TJ, Peterson CB, Lawrence DA , et al. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem 2000; 275 (26) 19788-19794
• 174 Preissner KT, Grulich-Henn J, Ehrlich HJ , et al. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265 (30) 18490-18498
• 175 Lawrence DA, Palaniappan S, Stefansson S , et al. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem 1997; 272 (12) 7676-7680
• 176 Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81 (5) 1290-1299
• 177 Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. J Biochem 1988; 104 (4) 628-632
• 178 Vercauteren E, Mutch NJ, Declerck PJ, Gils A. Plasmin and the thrombin-thrombomodulin complex both contribute to thrombin-activatable fibrinolysis inhibitor activation in whole blood model thrombi. J Thromb Haemost 2013; 11 (1) 190-192
• 179 Carrieri C, Galasso R, Semeraro F, Ammollo CT, Semeraro N, Colucci M. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood. J Thromb Haemost 2011; 9 (1) 154-162
• 180 Wyseure T, Rubio M, Denorme F , et al. Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke. Blood 2015; 125 (8) 1325-1332
• 181 Denorme F, Wyseure T, Peeters M , et al. Inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice. Stroke 2016; 47 (9) 2419-2422
• 182 Wang X, Palasubramaniam J, Gkanatsas Y , et al. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res 2014; 114 (7) 1083-1093
• 183 Nachman RL. Immunologic studies of platelet protein. Blood 1965; 25: 703-711